A
A. Stirling
Researcher at Wesley Hospital
Publications - 8
Citations - 134
A. Stirling is an academic researcher from Wesley Hospital. The author has contributed to research in topics: Prostate cancer & Internal medicine. The author has an hindex of 1, co-authored 2 publications receiving 6 citations.
Papers
More filters
Journal ArticleDOI
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
Johann S. de Bono,Niven Mehra,Giorgio V. Scagliotti,Elena Castro,Tanya B. Dorff,A. Stirling,Arnulf Stenzl,Mark D. Fleming,Celestia S. Higano,Fred Saad,Consuelo Buttigliero,Inge M. van Oort,A. Douglas Laird,Marielena Mata,Hsiang-Chun Chen,Cynthia G. Healy,Akos Czibere,Karim Fizazi +17 more
TL;DR: In this paper, the authors assessed the PARP inhibitor talazoparib in metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair (HRR).
Journal ArticleDOI
LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)
Chris Parker,N.W. Clarke,Audrey Cook,Charles Catton,William Cross,Howard Kynaston,John P Logue,Peter Mosborg Petersen,P Neville,Rambachan Persad,HA Payne,F. Saad,A. Stirling,Wendy R. Parulekar,Mahesh K. B. Parmar,Matthew R. Sydes +15 more
TL;DR: There is good evidence on the use of ADT with primary prostatectomy (RT) as initial treatment for prostate cancer, but there is uncertainty about the role and duration of ADTs with RT after radical prostatectoma (RP) as mentioned in this paper .
Journal ArticleDOI
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra,Karim Fizazi,Johann S. de Bono,Philippe Barthélémy,Tanya B. Dorff,A. Stirling,Jean-Pascal Machiels,Davide Bimbatti,Deepak Kilari,Herlinde Dumez,Consuelo Buttigliero,Inge M. van Oort,Elena Castro,Hsiang Chun Chen,Nicola Di Santo,Liza DeAnnuntis,Cynthia G. Healy,Giorgio V. Scagliotti +17 more
TL;DR: Common TEAEs associated with talazoparib could be managed through dose modifications/supportive care and demonstrated efficacy and a manageable safety profile support continued evaluation of talazobarib in mCRPC.
Journal ArticleDOI
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
Fred Saad,Johann S. de Bono,Philippe Barthélémy,Tanya B. Dorff,Niven Mehra,Giorgio V. Scagliotti,A. Stirling,Jean-Pascal Machiels,V. Renard,Marco Maruzzo,Celestia S. Higano,Howard Gurney,Cynthia G. Healy,H. Bhattacharyya,Bhakti Arondekar,A. Niyazov,Karim Fizazi +16 more
TL;DR: TALAPRO-1 is a single-arm, phase 2 study in men with mCRPC DDR alterations either directly or indirectly involved in HRR, who previously received one to two taxane-based chemotherapy regimens for advanced prostate cancer as mentioned in this paper .
Journal ArticleDOI
138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin
Niven Mehra,Karim Fizazi,A.D. Laird,Philippe Barthélémy,Remy Delva,Tanya B. Dorff,M. Maruzzo,A. Stirling,J-P. Machiels,Herlinde Dumez,V. Renard,Lee A. Albacker,Julia Hopkins,H-C. Chen,Marielena Mata,N. Di Santo,Cynthia G. Healy,I.M. van Oort,Consuelo Buttigliero,J.S. de Bono +19 more